Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$45.6MFederal grants as PI41 awards
10Patents grantedLatest Jun 2, 2026
25Papers1,012 citations
Federal awards and patents by year
AwardsPatents
41 awards · $45.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 6, 2026 | NIH | SBIR Phase II Direct-from-specimen characterization of bloodstream infections | $1.0M | HELIXBIND, INC. |
| Jul 16, 2026 | NIH | SBIR Phase II Automated system for the direct from blood characterization of bloodstream infections | $1.0M | HELIXBIND, INC. |
| Jun 30, 2026 | NIH | SBIR Phase II An automated culture-free system for the identification of bloodstream infections direct from blood | $1.0M | HELIXBIND, INC. |
| Jun 19, 2026 | NIH | SBIR Phase II Direct-from-specimen identification of pathogens common in endocarditis | $987K | HELIXBIND, INC. |
| Jul 2, 2025 | NIH | SBIR Phase II An automated culture-free system for the identification of bloodstream infections direct from blood | $1.0M | HELIXBIND, INC. |
| Jun 13, 2025 | NIH | SBIR Phase II Diagnostic tool for assessment and tracking of microbial load in bloodstream infections | $996K | HELIXBIND, INC. |
| Dec 12, 2024 | NIH | SBIR Phase II Direct-from-specimen identification of pathogens common in endocarditis | $1.0M | HELIXBIND, INC. |
| Jul 26, 2024 | NIH | SBIR Phase II Direct from blood identification of bloodstream infections in newborns | $996K | HELIXBIND, INC. |
| Jul 24, 2024 | NIH | SBIR Phase II Direct detection and identification of antimicrobial resistance genes in bloodstream infections | $1.0M | HELIXBIND, INC. |
| Jul 8, 2024 | NIH | SBIR Phase II An automated culture-free system for the identification of bloodstream infections direct from blood | $1.0M | HELIXBIND, INC. |
| May 31, 2024 | NIH | SBIR Phase II Diagnostic tool for assessment and tracking of microbial load in bloodstream infections | $985K | HELIXBIND, INC. |
| Jan 19, 2024 | NIH | SBIR Phase II Direct-from-specimen identification of pathogens common in endocarditis | $1.0M | HELIXBIND, INC. |
| Aug 3, 2023 | NIH | SBIR Phase II Direct detection and identification of antimicrobial resistance genes in bloodstream infections | $1.0M | HELIXBIND, INC. |
| Jul 7, 2023 | NIH | SBIR Phase II Direct from blood identification of bloodstream infections in newborns | $991K | HELIXBIND, INC. |
| Jun 23, 2023 | NIH | SBIR Phase II Diagnostic tool for assessment and tracking of microbial load in bloodstream infections | $1.1M | HELIXBIND, INC. |
| Mar 28, 2023 | NIH | SBIR Phase II An Integrated Device for Rapid Bacteremia Diagnosis Direct from Whole Blood | $1.0M | HELIXBIND, INC. |
| Mar 13, 2023 | NIH | SBIR Phase II Massively Multiplexed dsDNA Invasion Arrays | $1.0M | HELIXBIND, INC. |
| Aug 9, 2022 | NIH | SBIR Phase II Direct detection and identification of antimicrobial resistance genes in bloodstream infections | $1.1M | HELIXBIND, INC. |
| Aug 1, 2022 | NIH | SBIR Phase II Direct from blood identification of bloodstream infections in newborns | $995K | HELIXBIND, INC. |
| May 16, 2022 | NIH | SBIR Phase II Development of an automated IVD for the ultra-sensitive, direct, molecular detection of Borrelia for early Lyme Disease | $981K | HELIXBIND, INC. |
| Apr 1, 2022 | NIH | SBIR Phase II Massively Multiplexed dsDNA Invasion Arrays | $1.0M | HELIXBIND, INC. |
| Mar 29, 2022 | NIH | SBIR Phase II A Culture-Free Platform for Rapid Fungal Pathogen Identification | $1.0M | HELIXBIND, INC. |
| Mar 29, 2022 | NIH | SBIR Phase II An Integrated Device for Rapid Bacteremia Diagnosis Direct from Whole Blood | $1.0M | HELIXBIND, INC. |
| May 12, 2021 | NIH | SBIR Phase II Development of an automated IVD for the ultra-sensitive, direct, molecular detection of Borrelia for early Lyme Disease | $992K | HELIXBIND, INC. |
| Apr 14, 2021 | NIH | SBIR Phase II Massively Multiplexed dsDNA Invasion Arrays | $1.0M | HELIXBIND, INC. |
| Mar 26, 2021 | NIH | SBIR Phase II An Integrated Device for Rapid Bacteremia Diagnosis Direct from Whole Blood | $1.0M | HELIXBIND, INC. |
| Mar 18, 2021 | NIH | SBIR Phase II A Culture-Free Platform for Rapid Fungal Pathogen Identification | $1.0M | HELIXBIND, INC. |
| Dec 17, 2020 | NIH | SBIR Phase II An automated platform for direct-from-specimen identification of pathogens common in endocarditis | $1.0M | HELIXBIND, INC. |
| Jun 15, 2020 | NIH | SBIR Phase II Development of an automated IVD for the ultra-sensitive, direct, molecular detection of Borrelia for early Lyme Disease | $3.0M | HELIXBIND, INC. |
| Apr 16, 2020 | NIH | SBIR Phase II A Culture-Free Platform for Rapid Fungal Pathogen Identification | $1.0M | HELIXBIND, INC. |
| Jan 3, 2020 | NIH | SBIR Phase II An automated platform for direct-from-specimen identification of pathogens common in endocarditis | $998K | HELIXBIND, INC. |
| 2019 | NIH | SBIR Phase II An automated platform for direct-from-specimen identification of pathogens common in endocarditis | $3.0M | HELIXBIND, INC. |
| Aug 14, 2018 | NIH | SBIR Phase II A sample-to-answer diagnostic for neonatal bloodstream infections | $997K | HELIXBIND, INC. |
| Jul 20, 2018 | NIH | SBIR Phase II An Integrated Device for Rapid Bacteremia Diagnosis from Whole Blood | $411K | HELIXBIND, INC. |
| Jan 4, 2018 | NIH | SBIR Phase I Culture-free identification of pathogens common in endocarditis directly from patient specimens | $300K | HELIXBIND, INC. |
| Sep 1, 2017 | NIH | SBIR Phase II A sample-to-answer diagnostic for neonatal bloodstream infections | $2.0M | HELIXBIND, INC. |
| Jun 28, 2017 | NIH | SBIR Phase II An Integrated Device for Rapid Bacteremia Diagnosis from Whole Blood | $984K | HELIXBIND, INC. |
| Jul 19, 2016 | NIH | SBIR Phase II A Culture-Free Platform for Rapid Pathogen Identification | $697K | HELIXBIND, INC. |
| Jul 1, 2016 | NIH | SBIR Phase II An Integrated Device for Rapid Bacteremia Diagnosis from Whole Blood | $2.4M | HELIXBIND, INC. |
| Sep 18, 2015 | NIH | SBIR Phase I A sample-to-answer diagnostic for neonatal blood stream infections | $225K | HELIXBIND, INC. |
| Aug 1, 2015 | NIH | SBIR Phase II A Culture-Free Platform for Rapid Pathogen Identification | $1.5M | HELIXBIND, INC. |
11 patents as inventor
- US 10730041HELIXBIND, INC.Aug 4, 2020
- US 11091814HELIXBIND, INC.Aug 17, 2021
- US 11414712HELIXBIND, INC.Aug 16, 2022
- US 11590507HELIXBIND, INC.Feb 28, 2023
- US 11713330HELIXBIND, INC.Aug 1, 2023
- US 11840721HELIXBIND, INC.Dec 12, 2023
- US 11975320HELIXBIND, INC.May 7, 2024
- US 12516387HELIXBIND, INC.Jan 6, 2026
- US 12589387HELIXBIND, INC.Mar 31, 2026
- US 12644158HELIXBIND, INC.Jun 2, 2026
- US HELIXBIND, INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#1
Awards as PI#2
Patents#12
Companies
- HELIXBIND, INC.Leads (SEC Form D) · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.